Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Low Dose Epcoritamab Plus Gemcitabine/Oxaliplatin in Treatment of Transplant Eligible Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Perla R Colunga-Pedraza, MD
- Phone Number: +52 8110761973
- Email: alrep_rcp@gmail.com
Study Contact Backup
- Name: Natalia Huergo-Treviño, MD
- Phone Number: +524442416594
- Email: nat.hue94@gmail.com
Study Locations
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64640
- Recruiting
- Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant
- ECOG 0-2
- Women of reproductive age who agree on getting a contraceptive method
- Subjects who fulfill Lugano´s criteria for disease activity
- Subjects who voluntarily accept to participate in this study
Exclusion Criteria:
- Active bacterial, viral or fungal infection
- Subjects who have already received an autologous o allogeneic stem cell transplantation
- Subjects with other active neoplasias
- Subjects with end-stage failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Epcoritamab + GemOx
Subjects will receive Gemcitabine/Oxaliplatin at usual doses as well as Epcoritamab with 2 step up doses followed by 12 mg weekly for 3 cycles.
|
Subjects will receive 2 step up doses of Epcoritamab (0.16 mg and 0.8 mg) followed by 12 mg weekly, for a total of three 21-day cycles (8 applications)
Subjects will receive gemcitabine 1000 mg/m2 on days 1 and 15 of the three 21-day cycles.
Subjects will receive oxaliplatin 100 mg/m2 on day 1 of three 21-day cycles.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine ORR and CR after GemOx plus low-dose Epcoritamab
Time Frame: From enrollment to the end of treatment at 14 weeks
|
Determine ORR and CR after 3 cycles of GemOx plus low-dose Epcoritamab based on PET-CT
|
From enrollment to the end of treatment at 14 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Establish feasibility
Time Frame: From enrollment up to day 29
|
Determine the number of subjects that complete the first cycle without need for hospitalization
|
From enrollment up to day 29
|
|
Describe cytokine release syndrome incidence
Time Frame: From day 1 up to day 29
|
Describe the number of subjects who develop grade 2-4 cytokine release syndrome during the first cycle of treatment
|
From day 1 up to day 29
|
|
Describe immune effector cell- associated neurotoxicity syndrome incidence
Time Frame: From day 1 up to week 10
|
Describe the number of subjects that develop immune effector cell-associated neurotoxicity syndrome
|
From day 1 up to week 10
|
|
Describe adverse events
Time Frame: From day 1 up to week 10
|
Describe the number of subjects that develop any adverse events
|
From day 1 up to week 10
|
|
Determine number of patients that follow through with transplant
Time Frame: From day one up through study completion, an average of 1 year
|
Determine the number of patients that go through with stem cell transplant after finishing 3 cycles of Epcoritamab + GemOx
|
From day one up through study completion, an average of 1 year
|
|
Duration of response
Time Frame: From week 18 through study completion, an average of 1 year
|
Determine the duration of response
|
From week 18 through study completion, an average of 1 year
|
|
Progression free survival
Time Frame: From week 18 up to six and twelve months
|
Report the subjects´ progression free survival
|
From week 18 up to six and twelve months
|
|
Overall survival
Time Frame: From day 1 to twelve months
|
Report the overall survival
|
From day 1 to twelve months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Perla R Colunga-Pedraza, MD, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Publications and helpful links
General Publications
- Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.
- Li T, Gibiansky L, Parikh A, Putnins M, Chiu CW, Sacchi M, Feng H, Ahmadi T, Gupta M, Xu S. Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma. Clin Pharmacol Ther. 2025 May;117(5):1437-1450. doi: 10.1002/cpt.3588. Epub 2025 Feb 11.
- Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Jurczak W, Do YR, Gasiorowski R, Lewis DJ, Kim TM, van der Poel M, Poon ML, Feldman T, Linton KM, Sureda A, Hutchings M, Dinh MH, Kilavuz N, Soong D, Mark T, Sacchi M, Phillips T, Lugtenburg PJ. Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024 Dec;38(12):2653-2662. doi: 10.1038/s41375-024-02410-8. Epub 2024 Sep 25.
- Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2023 Dec;114(12):4643-4653. doi: 10.1111/cas.15996. Epub 2023 Nov 3.
- Brody JD, Jorgensen J, Belada D, Costello R, Trneny M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, Andre M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 2025 Apr 10;145(15):1621-1631. doi: 10.1182/blood.2024026830.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma
- Hemic and Lymphatic Diseases
- Lymphoma, Large B-Cell, Diffuse
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Coordination Complexes
- Deoxycytidine
- Cytidine
- Pyrimidine Nucleosides
- Pyrimidines
- Oxaliplatin
- Gemcitabine
Other Study ID Numbers
Other Study ID Numbers
- HE26-00003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.